Oxytocin antagonists: the next frontier in PE treatment
| dc.authorid | 0000-0002-2530-7012 | |
| dc.contributor.author | Gül, Murat | |
| dc.contributor.author | Şerefoğlu, Ege Can | |
| dc.date.accessioned | 2020-02-13T07:39:34Z | |
| dc.date.available | 2020-02-13T07:39:34Z | |
| dc.date.issued | 2019 | |
| dc.department | Tıp Fakültesi | |
| dc.description | Gül, Murat ( Aksaray, Yazar ) | |
| dc.description.abstract | Premature ejaculation (PE) is the most common sexual dysfunction among men worldwide1 . The exact pathophysiology of PE is unknown, and current treatment modalities are inadequate . Dapoxetine, a short-acting selective serotonin reuptake inhibitor, is the only medication approved in Europe, but it has not yet been approved in the USA owing to its limited efficacy and several safety concerns . Thus, the search for an efficacious and safe treatment for PE is ongoing | |
| dc.identifier.doi | 10.1038/s41585-019-0238-7 | |
| dc.identifier.endpage | 697 | en_US |
| dc.identifier.issn | 1759-4812 | |
| dc.identifier.issue | 12 | en_US |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 696 | en_US |
| dc.identifier.uri | https:/dx.doi.org/10.1038/s41585-019-0238-7 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12451/7179 | |
| dc.identifier.volume | 16 | en_US |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Nature Research | |
| dc.relation.ispartof | Nature Reviews Urology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Cligosiban | |
| dc.subject | Oxytocin | |
| dc.subject | Pyridine Derivative | |
| dc.subject | Triazole Derivative | |
| dc.title | Oxytocin antagonists: the next frontier in PE treatment | |
| dc.type | Article |
